Atea AVIR: C-BEYOND Phase 3 erreichte primäre/sekundäre Endpunkte für BEM/RZR bei HCV

The document reports that the Phase 3 C-BEYOND trial met its primary endpoint of statistical non-inferiority versus SOF/VEL in the mITT population (93.9% vs 94.8% SVR) and all secondary endpoints, including the per-protocol analysis. The 8-week BEM/RZR regimen in non-cirrhotic patients achieved 93.5% SVR, supporting a potential best-in-class profile with shorter duration, low drug-drug interaction risk, and no food effect. NDA submission is now guided for Q2 2027 pending C-FORWARD results.

Kernfakten

Eingereicht: 12. Aug. 2026, 20:15
Ereignis: Topline-Ergebnisse
Richtung: Positiv
Unternehmen: AVIRAtea Pharmaceuticals
Asset: bemnifosbuvir/ruzasvir
Quelle: SEC 8-K
Belegstatus: Belegt
N MITT: 905
SVR MITT: 93,9 % vs. 94,8 %
N zirrhotisch: 184
SVR zirrhotisch: 95,4 % vs. 95,4 %
N nicht-zirrhotisch: 721
SVR nicht-zirrhotisch: 93,5 % vs. 94,6 %
Nicht-Unterlegenheitsgrenze: 5 %

Auszug aus der Quelle

EX-99.1 2 d165663dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027 AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV) Company Holding Conference Call Today at 4:30 pm ET BOSTON, Mass., August 12, 2026 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutic

SEC 8-K

Mehr zu diesem Asset

Beachtenswert

25. Juni 2026

11:00

AVIRAtea Pharmaceuticals

Atea schließt Patientenrekrutierung in Phase-3-C-FORWARD-HCV-Studie ab

Änderung im StudienregisterUnternehmensmitteilung